Filing Submission & Acceptance, Earnings Release Schedule, Agreement, and Conference Participation - Research Report on The Medicines Company, Covance, Air Methods, Auxilium, and Teleflex

07 Jan 2014

NEW YORK, January 7, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting The Medicines Company (NASDAQ: MDCO), Covance Inc. (NYSE: CVD), Air Methods Corporation (NASDAQ: AIRM), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

The Medicines Company Research Report  

On December 23, 2013, The Medicines Company (The Medicines) announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational intravenous antiplatelet agent, cangrelor. The Company notified that the filing is supported by the results of a comprehensive development program, including the data from four randomized, double-blind clinical trials (CHAMPION PHOENIX, CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE) conducted in more than 25,000 patients with coronary artery disease. "With the acceptance of the European filing, we look forward to working closely with the European Medicines Agency to advance the review process for cangrelor in Europe," said Simona Skerjanec, PharmD, MBA, Senior Vice President and Innovation Leader for Antiplatelet Therapies at The Medicines. "If the MAA review of cangrelor is successful, we anticipate the investigational product could be available to the European interventional cardiology community in 2015." The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Covance Inc. Research Report  

On January 2, 2014, Covance Inc. (Covance) announced that it will issue its Q4 2013 earnings release on February 4, 2014 after the market hours. The Company informed that it will also host a quarterly investor conference call on February 5, 2014, at 9:00 a.m. ET to discuss Q4 2013 earnings, which will be broadcast live over the Internet. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Air Methods Corporation Research Report

On January 2, 2014, Air Methods Corporation (Air Methods) announced that it has entered into an agreement with Haiti Air Ambulance Service, Inc. (Haiti Air Ambulance), to provide air medical transportation services to the Republic of Haiti. The Company informed that under the agreement, Air Methods will provide two Bell 407 helicopters and employ three pilots and two mechanics; and Haiti Air Ambulance will employ the clinical crew and provide medical direction. Aaron Todd, CEO of Air Methods said, "Air Methods is very pleased to support Haiti Air Ambulance's wonderful humanitarian effort to bring such a valuable health care resource to the citizens of Haiti. Patients with survivable injuries in Haiti too often die because of lack of trauma care in remote parts of the country and poor road conditions. The ability of this service to extend the reach of trauma services in an expeditious way will save and improve hundreds of Haitian lives annually." The Full Research Report on Air Methods Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Auxilium Pharmaceuticals, Inc. Research Report  

On December 20, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA), requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture (DC) cords concurrently. "We are pleased to present the multicords BLA filing to the FDA ahead of schedule, especially given the estimated high prevalence of multiple cords among patients suffering from Dupuytren's contracture," said Adrian Adams, CEO and President of Auxilium. "This is an important milestone for Auxilium and, importantly, for patients, as we believe that a potential label expansion would provide a non-surgical option for treating multiple cords during one office procedure." The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Teleflex Incorporated Research Report

On January 2, 2014, Teleflex Incorporated (Teleflex) reported that it will participate at the 32nd Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel in San Francisco, California. The Company informed that Teleflex's Chairman, President, and CEO, Benson F. Smith, is scheduled to make the presentation on Thursday, January 16, 2014, at 10:30 a.m. PT. Teleflex added that an audio webcast and an accompanying slide presentation will be available on the Investors section of the Company's website. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information